Loading...

Neovacs

BST:0LW
Snowflake Description

Moderate growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0LW
BST
€25M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. The last earnings update was 171 days ago. More info.


Add to Portfolio Compare Print Invest
0LW Share Price and Events
Price Volatility
0LW
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Neovacs undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Neovacs to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Neovacs.

BST:0LW Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BST:0LW
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 9.5%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 0.76
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.757 (1 + (1- 33%) (9.85%))
0.807
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.81
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.54% + (0.807 * 9.46%)
8.18%

Discounted Cash Flow Calculation for BST:0LW using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Neovacs is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

BST:0LW DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (EUR, Millions) 9.30 11.07 13.06 15.28 17.72
Source Analyst x1 Est @ 19%, capped from 57.96% Est @ 18%, capped from 57.96% Est @ 17%, capped from 57.96% Est @ 16%, capped from 57.96%
Present Value
Discounted (@ 8.18%)
8.60 9.46 10.32 11.16 11.97
Present value of next 5 years cash flows €51.49
BST:0LW DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= €17.72 × (1 + 0.54%) ÷ (8.18% – 0.54%)
€233.45
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= €233.45 ÷ (1 + 8.18%)5
€157.60
BST:0LW Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= €51.49 + €157.60
€209.09
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €209.09 / 96.34
€2.34
BST:0LW Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BST:0LW represents 1.07617x of ENXTPA:ALNEV
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.07617x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 2.17 x 1.07617
€2.34
Value per share (EUR) From above. €2.34
Current discount Discount to share price of €0.28
= -1 x (€0.28 - €2.34) / €2.34
88.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Neovacs is available for.
Intrinsic value
>50%
Share price is €0.28 vs Future cash flow value of €2.34
Current Discount Checks
For Neovacs to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Neovacs's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Neovacs's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Neovacs's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Neovacs's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:0LW PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2017-12-31) in EUR €-0.21
ENXTPA:ALNEV Share Price ** ENXTPA (2018-07-18) in EUR €0.26
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 31.17x
Germany Market PE Ratio Median Figure of 407 Publicly-Listed Companies 18.17x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Neovacs.

BST:0LW PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:ALNEV Share Price ÷ EPS (both in EUR)

= 0.26 ÷ -0.21

-1.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Neovacs is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Neovacs is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Neovacs's expected growth come at a high price?
Raw Data
BST:0LW PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.22x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
109%per year
Europe Biotechs Industry PEG Ratio Median Figure of 16 Publicly-Listed Biotechs Companies 1.61x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.37x

*Line of best fit is calculated by linear regression .

BST:0LW PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= -1.22x ÷ 109%

-0.01x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Neovacs is loss making, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Neovacs's assets?
Raw Data
BST:0LW PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2017-12-31) in EUR €0.02
ENXTPA:ALNEV Share Price * ENXTPA (2018-07-18) in EUR €0.26
Germany Biotechs Industry PB Ratio Median Figure of 13 Publicly-Listed Biotechs Companies 2.43x
Germany Market PB Ratio Median Figure of 547 Publicly-Listed Companies 1.86x
BST:0LW PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:ALNEV Share Price ÷ Book Value per Share (both in EUR)

= 0.26 ÷ 0.02

15.83x

* Primary Listing of Neovacs.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Neovacs is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Neovacs's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Neovacs has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Neovacs expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
109%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Neovacs expected to grow at an attractive rate?
  • Neovacs's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Neovacs's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Neovacs's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BST:0LW Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:0LW Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 109%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 50.8%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 23.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:0LW Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:0LW Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2019-12-31 15 10 1
2018-12-31 -8
BST:0LW Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2017-12-31 1 -14 -15
2017-09-30 1 -14 -15
2017-06-30 1 -14 -15
2017-03-31 1 -12 -15
2016-12-31 0 -11 -14
2016-09-30 0 -10 -10
2016-06-30 0 -9 -7
2016-03-31 0 -8 -6
2015-12-31 0 -8 -5
2015-09-30 0 -7 -7
2015-06-30 0 -7 -9
2015-03-31 0 -8 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Neovacs's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Neovacs is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:0LW Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Neovacs Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:0LW Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2019-12-31
2018-12-31 -0.18 -0.18 -0.18 1.00
BST:0LW Past Financials Data
Date (Data in EUR Millions) EPS *
2017-12-31 -0.21
2017-09-30 -0.22
2017-06-30 -0.29
2017-03-31 -0.28
2016-12-31 -0.31
2016-09-30 -0.23
2016-06-30 -0.16
2016-03-31 -0.13
2015-12-31 -0.15
2015-09-30 -0.21
2015-06-30 -0.35
2015-03-31 -0.33

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Neovacs will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Neovacs's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Neovacs has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Neovacs performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Neovacs's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Neovacs does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Neovacs's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Neovacs's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Neovacs's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Neovacs Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:0LW Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2017-12-31 0.81 -14.84 2.99
2017-09-30 0.78 -15.06 2.91
2017-06-30 0.74 -15.28 2.83
2017-03-31 0.54 -14.61 2.75
2016-12-31 0.34 -13.93 2.67
2016-09-30 0.25 -10.26 2.60
2016-06-30 0.16 -6.59 2.52
2016-03-31 0.15 -5.64 2.46
2015-12-31 0.15 -4.68 2.40
2015-09-30 0.16 -6.60 2.35
2015-06-30 0.17 -8.52 2.30
2015-03-31 0.16 -8.02 2.11
2014-12-31 0.14 -7.51 1.92
2014-09-30 0.11 -7.48 1.99
2014-06-30 0.08 -7.45 2.05
2014-03-31 0.06 -7.16 2.30
2013-12-31 0.03 -6.87 2.55
2013-09-30 0.01 -6.65 2.55
2013-06-30 0.00 -6.43 2.55
2013-03-31 0.05 -6.79 2.53
2012-12-31 0.10 -7.15 2.51
2012-09-30 0.10 -7.46 2.50
2012-06-30 0.10 -7.77 2.50
2012-03-31 0.23 -7.94 2.45
2011-12-31 0.36 -8.11 2.40

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Neovacs has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Neovacs has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Neovacs improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Neovacs's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Neovacs has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Neovacs's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Neovacs's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Neovacs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Neovacs's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Neovacs's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 4.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Neovacs Company Filings, last reported 9 months ago.

BST:0LW Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2017-12-31 1.12 2.45 5.15
2017-09-30 1.12 2.45 5.15
2017-06-30 -0.92 0.80 1.83
2017-03-31 -0.92 0.80 1.83
2016-12-31 1.82 0.81 3.95
2016-09-30 1.82 0.81 3.95
2016-06-30 7.76 0.80 9.17
2016-03-31 7.76 0.80 9.17
2015-12-31 6.37 0.74 6.09
2015-09-30 6.37 0.74 6.09
2015-06-30 2.59 1.48 12.30
2015-03-31 2.59 1.48 12.30
2014-12-31 5.87 1.29 5.63
2014-09-30 5.87 1.29 5.63
2014-06-30 2.62 1.20 2.86
2014-03-31 2.62 1.20 2.86
2013-12-31 3.72 1.12 4.02
2013-09-30 3.72 1.12 4.02
2013-06-30 7.31 1.03 8.27
2013-03-31 7.31 1.03 8.27
2012-12-31 3.88 0.98 4.35
2012-09-30 3.88 0.98 4.35
2012-06-30 7.35 0.96 6.64
2012-03-31 7.35 0.96 6.64
2011-12-31 10.83 0.89 10.59
  • Neovacs's level of debt (219%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (24.9% vs 219% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Neovacs has less than a year of cash runway based on current financial obligations.
  • Neovacs has less than a year of cash runway if financial obligations continue to grow at historical rates of 39.5% each year.
X
Financial health checks
We assess Neovacs's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Neovacs has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Neovacs's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Neovacs dividends.
If you bought €2,000 of Neovacs shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Neovacs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Neovacs's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:0LW Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 322 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:0LW Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Neovacs has not reported any payouts.
  • Unable to verify if Neovacs's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Neovacs's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Neovacs has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Neovacs's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Neovacs afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Neovacs has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Neovacs's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Miguel Sieler, image provided by Google.
Miguel Sieler
COMPENSATION €243,267
AGE 68
TENURE AS CEO 5 years
CEO Bio

Mr. Miguel Sieler has been the Chief Executive Officer at Neovacs S.A. since October 17, 2013. Mr. Sieler served as the Chairman and Chief Executive Officer of Bayer Group in France since 1998 until 2008. He served as CEO Circle, Life Sciences and prior to that as a Venture Partner at the firm. Mr. Sieler served in various senior positions at Bayer AG, Leverkusen, (Germany) from 1975 to 2008. He joined Bayer AG, Leverkusen, (Germany) in 1975 for an international career which started at the group headquarters in Germany. He further served in various senior management positions in Brussels and Sao Paulo before becoming President of Bayer in Korea. He served as the Chief Executive Officer and Chairman of Bayer Pharma from 1995 to 1998 and at Bayer AG from 1998 to 2008. He serves as the Chairman of Wittycell and Chairman of PlasmaPrime. He serves as the Chairman of Stratoz. He serves as a Director of Neovacs S.A. and Ethypharm SA. He served as a Director of ABIVAX S.A. until September 6, 2015. Mr. Sieler served as a Director of Nexity S.A. from May 10, 2005 to January 27, 2017. Mr. Sieler has over 32 years experience in the chemical and pharmaceutical industry. Mr. Sieler holds a Master of Law from the University of Tubingen, Germany and graduated from the Institut d’Etudes Politiques de Paris, France.

CEO Compensation
  • Miguel's compensation has increased whilst company is loss making.
Management Team Tenure

Average tenure of the Neovacs management team in years:

4
Average Tenure
  • The tenure for the Neovacs management team is about average.
Management Team

Miguel Sieler

TITLE
Chief Executive Officer & Director
COMPENSATION
€243K
AGE
68
TENURE
5 yrs

Daniel Zagury

TITLE
Founder
COMPENSATION
€14K

Baptiste Pourtout

TITLE
Financial Director

Géraldine Grouard-Vogel

TITLE
Chief Scientific Officer
TENURE
3.6 yrs

Nathalie Thomas-Pujol

TITLE
Head of Regulatory Affairs
TENURE
4.3 yrs

Thérèse Croughs

TITLE
Chief Medical Officer
AGE
54
TENURE
3.6 yrs

Bernard Fanget

TITLE
Vice President of Pharmaceutical Development

Olivier Dhellin

TITLE
Director of Pharmaceutical Development & Quality Assurance
Board of Directors Tenure

Average tenure and age of the Neovacs board of directors in years:

7.4
Average Tenure
69
Average Age
  • The tenure for the Neovacs board of directors is about average.
Board of Directors

Jean-Jacques Bertrand

TITLE
Chairman
COMPENSATION
€24K
AGE
79
TENURE
8.7 yrs

Miguel Sieler

TITLE
Chief Executive Officer & Director
COMPENSATION
€243K
AGE
68

Daniel Zagury

TITLE
Founder
COMPENSATION
€14K

Jacques Banchereau

TITLE
Chairman of Scientific Advisory Board & Director
COMPENSATION
€10K

Armand Bensussan

TITLE
Vice Chairman of Scientific Research Committee

Bob Gallo

TITLE
Vice Chairman of Scientific Research Committee
AGE
81

Thomas Kündig

TITLE
Member of Scientific Research Committee
COMPENSATION
€3K

Arsène Burny

TITLE
Member of Scientific Research Committee

Arlene Morris

TITLE
Independent Director
COMPENSATION
€12K
AGE
66
TENURE
7.4 yrs

Patrick Valroff

TITLE
Independent Director
COMPENSATION
€13K
AGE
69
TENURE
7.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Start End Shares Value (USD)
X
Management checks
We assess Neovacs's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Neovacs has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Company Info

Map
Description

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company’s product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Details
Name: Neovacs S.A.
0LW
Exchange: BST
Founded: 1993
€24,902,792
96,335,754
Website: http://www.neovacs.fr
Address: Neovacs S.A.
3-5, Impasse Reille,
Paris,
Ile-de-France, 75014,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA ALNEV Common Shares Euronext Paris FR EUR 20. Apr 2009
DB 0LW Common Shares Deutsche Boerse AG DE EUR 20. Apr 2009
BST 0LW Common Shares Boerse-Stuttgart DE EUR 20. Apr 2009
LSE 0W8U Common Shares London Stock Exchange GB EUR 20. Apr 2009
Number of employees
Current staff
Staff numbers
25
Neovacs employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/10/15 18:40
End of day share price update: 2018/07/18 00:00
Last estimates confirmation: 2018/09/11
Last earnings filing: 2018/04/27
Last earnings reported: 2017/12/31
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.